Corbus Pharmaceuticals Holdings, Inc.
CRBPNasdaq
$9.01
↑ +2.4%Jul 17 close · end-of-day
Price
1Y↑ +5.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$168.5M
Enterprise Value
$30.3M
P/E
—
P/S
—
P/B
1.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$84.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-66.9%
ROIC
—
Debt / Equity
—
Net Cash
$138.2M
Return 1Y
+6.5%
Company profile
Corbus Pharmaceuticals Holdings, Inc. focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus. CRB-601, an anti-integrin monoclonal antibody (mAb) that inhibits the activation of transforming growth factor ß (TGFß)
- CEO
- Yuval Cohen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Massachusetts
- Website
- corbuspharma.com
Management & directors
- Saxena Nishant CChief Business Officer
- Smethurst DominicChief Medical Officer
- Hodgson IanChief Operating Officer
- Cohen YuvalChief Executive Officer
- Moran Sean F.Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
CRBP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.23↓ -11.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.9M | $881,705.00 | $0.00 | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$122.8M | -$56.0M | -$39.8M | -$45.1M | -$48.7M | -$85.3M |
| Net income | -$111.3M | -$45.6M | -$42.3M | -$44.6M | -$40.2M | -$78.5M |
| Diluted EPS | — | -$11.15 | -$10.15 | -$10.31 | -$3.68 | -$5.90 |
| Operating cash flow | -$99.7M | -$48.2M | -$37.5M | -$36.1M | -$41.8M | -$64.5M |
| Free cash flow | -$100.2M | -$48.2M | -$37.6M | -$36.1M | -$41.8M | -$64.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -3119.2% | -6350.1% | — | — | — | — |
| Net margin | -2826.1% | -5176.4% | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$11.0M | -$15.5M | -$12.6M | -$19.8M | -$19.2M | -$24.4M | -$22.0M | -$24.3M |
| Net income | -$10.0M | -$13.8M | -$9.5M | -$17.0M | -$17.7M | -$23.3M | -$20.6M | -$23.0M |
| Diluted EPS | -$0.90 | -$1.15 | -$0.80 | -$1.39 | -$1.44 | -$1.90 | -$1.17 | -$1.23 |
| Operating cash flow | -$8.9M | -$13.9M | -$10.9M | -$16.4M | -$16.6M | -$15.6M | -$15.9M | -$25.6M |
| Free cash flow | — | — | — | -$16.4M | — | — | — | -$25.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-10 | Jenkins John Kenneth | Sale | 4,800 | $7.91 | $37,985.76 | filing |
| 2026-06-10 | Altmeyer Anne | Sale | 2,412 | $7.91 | $19,087.84 | filing |
| 2026-06-10 | Kung Winston | Sale | 2,026 | $7.91 | $16,033.16 | filing |
| 2026-06-03 | Saxena Nishant C· Chief Business Officer | Buy | 9,000 | $7.58 | $68,220.00 | filing |
| 2026-06-02 | Saxena Nishant C· Chief Business Officer | Buy | 4,500 | $7.33 | $32,998.50 | filing |
| 2026-05-21 | Saxena Nishant C· Chief Business Officer | Award | 58,300 | $0.00 | $0.00 | filing |
| 2026-05-19 | Jacques Rachelle Suzanne | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-19 | Kung Winston | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-19 | Jenkins John Kenneth | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-19 | Altmeyer Anne | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-19 | Ben Yong | Award | 3,800 | $0.00 | $0.00 | filing |
| 2026-05-19 | Pfeiffenberger Brent | Award | 7,500 | $0.00 | $0.00 | filing |
| 2026-03-02 | Smethurst Dominic· Chief Medical Officer | Sale | 6,097 | $8.30 | $50,601.44 | filing |
| 2026-02-17 | Hodgson Ian· Chief Operating Officer | Sale | 847 | $7.38 | $6,253.40 | filing |
| 2026-02-13 | Cohen Yuval· Chief Executive Officer | Sale | 13,871 | $7.78 | $107,952.44 | filing |
| 2026-02-13 | Moran Sean F.· Chief Financial Officer | Sale | 4,701 | $7.78 | $36,587.88 | filing |
| 2026-02-03 | Smethurst Dominic· Chief Medical Officer | Sale | 3,285 | $8.09 | $26,574.99 | filing |
| 2026-02-03 | Hodgson Ian· Chief Operating Officer | Sale | 2,415 | $8.09 | $19,537.11 | filing |
| 2026-01-14 | Smethurst Dominic· Chief Medical Officer | Award | 28,365 | $0.00 | $0.00 | filing |
| 2026-01-14 | Moran Sean F.· Chief Financial Officer | Award | 28,082 | $0.00 | $0.00 | filing |
| 2026-01-14 | Cohen Yuval· Chief Executive Officer | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-01-14 | Hodgson Ian· Chief Operating Officer | Award | 28,365 | $0.00 | $0.00 | filing |
| 2025-12-11 | Cormorant Asset Management, LLC | Sale | 30,029 | $11.46 | $344,012.22 | filing |
| 2025-10-27 | Cohen Yuval· Chief Executive Officer | Sale | 8,973 | $17.14 | $153,797.22 | filing |
| 2025-10-27 | Cohen Yuval· Chief Executive Officer | Option exercise | 8,973 | $4.26 | $38,224.98 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.